U.S. Patent 5,834,489: Ropivacaine Epidural Pain Treatment Claims, Scope, Expiration, and Patent Landscape

U.S. Patent No. 5,834,489 protects a method of relieving human pain by epidural administration of low-concentration ropivacaine, particularly ropivacaine hydrochloride, at concentrations below 0.5% by weight. The claims focus on reduced motor blockade, low drug concentration, epidural delivery, and, in claim 7, continuous infusion. The patent is expired and does not create current U.S. exclusivity for low-dose epidural ropivacaine therapy.[1]

What does U.S. Patent 5,834,489 cover?

The patent claims a therapeutic method rather than the ropivacaine molecule, a formulation composition standing alone, or a manufacturing process.

Claim element	Scope
Patient	Human
Therapeutic objective	Pain relief with minimal motor blockade
Active ingredient	A pharmaceutically acceptable salt of ropivacaine
Route	Epidural administration
Concentration in claim 1	Less than 0.5% by weight
Narrower ranges	0.01% to 0.45%; 0.01% to 0.3%
Specific concentrations	About 0.25% or about 0.3%
Specific salt	Ropivacaine hydrochloride
Administration mode	Continuous infusion under claim 7

The independent claim requires all of the following:

Treatment of a human.
Relief of pain.
A clinical result characterized as minimal motor blockade.
Epidural administration.
A composition containing a pharmaceutically acceptable ropivacaine salt.
Ropivacaine concentration below 0.5% by weight.

A product or treatment that omits any required element does not literally satisfy claim 1.

How do the individual claims differ?

Claims 2 through 7 narrow claim 1. They do not create independent protection for a different technology.

Claims 1 and 2: broad low-concentration ranges

Claim 1 covers any concentration below 0.5% by weight. Claim 2 narrows the range to 0.01% through 0.45%.

The practical difference is limited because claim 1 already covers the entire range in claim 2. Claim 2 may have relevance if claim 1 were challenged for validity or construed narrowly around the upper concentration boundary.

Claim 3: 0.01% to 0.3%

Claim 3 narrows the concentration range further. It covers commonly used dilute epidural ropivacaine concentrations, including 0.2%, 0.25%, and 0.3%.

A concentration below 0.01% would fall outside claim 3 but could remain within claim 1. A concentration above 0.3% but below 0.5% could remain within claims 1 and 2 while falling outside claim 3.

Claims 4 and 5: approximately 0.25% and 0.3%

The terms “about 0.25%” and “about 0.3%” introduce ordinary claim-construction issues concerning manufacturing tolerances, analytical precision, and the technical meaning of “about.” They are not necessarily limited to an exact laboratory value.

A formulation labeled 0.25% would be the clearest target of claim 4. A formulation labeled 0.3% would be the clearest target of claim 5.

Claim 6: ropivacaine hydrochloride

Claim 6 narrows the salt limitation to ropivacaine hydrochloride. This is commercially significant because ropivacaine hydrochloride is the active form used in Naropin products and in the principal U.S. clinical use of ropivacaine.[2]

Claim 7: continuous epidural infusion

Claim 7 applies when the composition is administered by continuous infusion. It depends on any one of claims 1 through 6. The claim therefore reaches continuous infusion at:

Any concentration below 0.5% under claim 1;
0.01% to 0.45% under claim 2;
0.01% to 0.3% under claim 3;
About 0.25% under claim 4;
About 0.3% under claim 5; and
Ropivacaine hydrochloride under claim 6.

A single bolus injection would not satisfy the continuous-infusion limitation of claim 7, although it could still fall within claims 1 through 6 if the other elements are met.

What is the strongest infringement theory under the patent?

The strongest literal infringement case would involve a human patient receiving ropivacaine hydrochloride epidurally at approximately 0.25% or 0.3% through a continuous infusion pump for analgesia, where the clinical protocol is intended to reduce motor blockade.

The central claim elements are route, concentration, and clinical purpose. Intravenous, intrathecal, peripheral nerve, wound infiltration, and subcutaneous administration would not literally satisfy the epidural-route limitation.

A treatment using 0.5% ropivacaine would fall outside the literal wording “less than 0.5%.” A treatment using 0.49% would remain within claim 1, assuming the other limitations are met.

How does “minimal motor blockade” affect claim scope?

“Minimal motor blockade” is a functional therapeutic limitation. It distinguishes the claimed method from higher-concentration local-anesthetic regimens that produce more pronounced motor impairment.

The patent does not appear to define the phrase as a single numerical motor-block score in the claims. Its scope would therefore depend on the specification, prosecution history, clinical evidence, and the ordinary meaning of the term to a person skilled in anesthesiology.

For enforcement or validity analysis, the following evidence would be material:

Concentration administered;
Epidural catheter location;
Bolus or infusion protocol;
Pain scores;
Motor-block assessment;
Dose and infusion rate;
Patient population;
Concomitant opioids or adjuvants; and
Clinical protocol language describing preservation of motor function.

A label that merely states “epidural analgesia” may not independently establish minimal motor blockade. A protocol expressly designed to provide analgesia while preserving lower-extremity motor function would present a stronger infringement record.

What formulations are protected by U.S. Patent 5,834,489?

The patent protects use of qualifying formulations, not every physical or chemical attribute of the formulation.

The claims can cover aqueous epidural solutions containing ropivacaine hydrochloride at concentrations such as:

Concentration	Claim position
0.01%	Claims 1, 2, and 3
0.1%	Claims 1, 2, and 3
0.2%	Claims 1, 2, and 3
About 0.25%	Claims 1 through 4
About 0.3%	Claims 1 through 5
0.45%	Claims 1 and 2
0.49%	Claim 1
0.5% exactly	Outside claim 1 based on the literal “less than 0.5%” limitation

The claims do not expressly require preservatives, a specific pH, a particular container, a particular dosage volume, or a specific infusion rate. Those features may be relevant to regulatory approval or product equivalence but are not apparent limitations of the issued claims.

When did U.S. Patent 5,834,489 lose exclusivity?

U.S. Patent 5,834,489 is expired. Its enforceable term ended in the mid-2010s under the 20-year patent-term framework applicable to the application family.[1]

Milestone	Event
November 10, 1998	U.S. patent issued
Mid-2010s	20-year patent term expired
Current status	Expired; no enforceable patent exclusivity

The patent therefore cannot presently block a generic manufacturer, hospital, compounder, or sponsor from practicing the claimed low-concentration epidural ropivacaine method in the United States, subject to other unexpired patents, regulatory requirements, and non-patent legal restrictions.

What is the Orange Book status of this patent?

U.S. Patent 5,834,489 is not a source of current Orange Book exclusivity for ropivacaine.

Orange Book-listed patents are tied to approved drug products and must satisfy FDA listing requirements. Method-of-use patents can be listed in some circumstances, but an expired patent cannot provide current patent protection against an abbreviated new drug application applicant.[3]

Naropin, the principal U.S. ropivacaine product, was approved by FDA in 1996. The FDA-approved label identifies ropivacaine hydrochloride injection for local or regional anesthesia, including epidural administration for surgery and labor-related analgesia.[2]

The practical position is:

The patent is expired.
It does not create a current barrier to an ANDA based on patent term.
Any historical Orange Book listing would have no remaining exclusionary effect.
Current generic-entry analysis must focus on other listed patents, regulatory exclusivity, product-specific requirements, and manufacturing capabilities.

Are Paragraph IV challenges still relevant?

No current Paragraph IV challenge is needed against Patent 5,834,489 because the patent has expired.

A Paragraph IV certification is used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. An expired patent does not provide an operative patent-term barrier requiring a generic applicant to wait for the patent’s expiration date.

Historical litigation or certification activity could still have commercial relevance for understanding the launch history of ropivacaine products, but it would not restore exclusivity to the patent.

What generic entry risks exist for low-dose epidural ropivacaine?

The patent-specific generic-entry risk is low because the patent has expired. The broader market risk depends on regulatory and commercial barriers.

Patent risk

No continuing exclusionary risk arises from U.S. Patent 5,834,489.

Regulatory risk

A generic ropivacaine injection sponsor must address:

Pharmaceutical equivalence;
Strength and concentration;
Sterility;
Container-closure system;
Labeling;
Route of administration;
Bioequivalence or applicable waiver standards; and
FDA requirements for injectable products.

Manufacturing risk

Sterile injectable manufacturing is a more significant barrier than the expired method patent. Critical issues include aseptic processing, terminal sterilization where applicable, particulate control, extractables and leachables, container integrity, and reliable supply of pharmaceutical-grade ropivacaine hydrochloride.

Commercial risk

The relevant competitive set includes branded Naropin, generic ropivacaine hydrochloride injections, bupivacaine products, levobupivacaine where available, and newer regional-anesthesia delivery systems. Hospitals often evaluate these products through formulary, contract, shortage, and supply-reliability criteria rather than patent position alone.

How does the patent compare with competing ropivacaine patent rights?

The ’489 patent is narrower than a compound patent and narrower than a broad formulation patent.

Patent category	Typical scope	Relevance to the ’489 patent
Compound patent	Ropivacaine molecule or stereoisomer	Broader chemical protection, generally expired for this product
Composition patent	Injectable formulation, excipients, pH, container, stability	May create separate product protection
Method-of-use patent	Treatment of pain using a defined concentration and route	Category of the ’489 patent
Delivery-system patent	Pumps, catheters, sustained-release systems	May apply independently
Manufacturing patent	Synthesis, purification, crystallization, or sterile filling	May create production barriers
Regulatory exclusivity	FDA exclusivity periods	Separate from patent rights

The ’489 patent’s commercial value was concentrated in the clinical use of dilute epidural ropivacaine, especially continuous infusion for analgesia with limited motor impairment. It did not control all uses of ropivacaine, all ropivacaine concentrations, or all ropivacaine dosage forms.

What is the current patent strength of U.S. Patent 5,834,489?

Its historical claim scope was commercially meaningful, but its current patent strength is zero because the patent is expired.

Factor	Assessment
Claim breadth	Moderate for low-concentration epidural use
Technical specificity	High
Product coverage	Ropivacaine salt, especially hydrochloride
Formulation coverage	Limited to use of the formulation, not a standalone composition
Continuous-infusion coverage	Narrower claim 7
Design-around potential during term	Available through route, concentration, indication, or dosing changes
Current enforceability	None after expiration
Current market blocking power	None

What licensing and settlement issues affect the patent?

No current licensing or settlement arrangement can extend the expired patent term. Any historical license involving Astra or an affiliated ropivacaine rights holder would have commercial significance only for the period before expiration, unless it included separate rights to unexpired formulation, manufacturing, delivery, or regulatory assets.

A settlement involving a generic manufacturer also would not revive the patent. Its continuing relevance would be limited to historical launch timing, damages, supply rights, or unrelated patent families.

What is the geographic coverage of the patent?

U.S. Patent 5,834,489 covered only conduct within the scope of U.S. patent law. It did not itself protect epidural ropivacaine use in Europe, Canada, Japan, or other jurisdictions.

Foreign counterparts would require separate analysis of:

Priority claims;
National-phase filings;
Patent grants;
Supplementary protection certificates;
Local patent-term adjustments;
Local litigation; and
Expiration or lapse events.

The U.S. expiration of the ’489 patent does not establish the status of corresponding foreign rights.

Key Takeaways

U.S. Patent 5,834,489 is a method-of-treatment patent.
Its core claim covers epidural administration of ropivacaine salt below 0.5% by weight to relieve pain with minimal motor blockade.
Claims 2 through 5 narrow the concentration, with specific protection around 0.25% and 0.3%.
Claim 6 specifies ropivacaine hydrochloride.
Claim 7 covers continuous infusion when the underlying claim limitations are met.
The patent does not broadly cover the ropivacaine molecule, every ropivacaine formulation, or non-epidural administration.
The patent expired in the mid-2010s and has no current blocking effect.
Paragraph IV litigation against this patent is no longer required for generic entry.
Current competitive risk is more likely to arise from sterile-injectable manufacturing, FDA requirements, other formulation or delivery patents, and hospital contracting than from the ’489 patent.

FAQs

Does 0.2% epidural ropivacaine fall within U.S. Patent 5,834,489?

Yes. A 0.2% epidural ropivacaine composition is within the numerical ranges of claims 1, 2, and 3 if the treatment is for pain relief with minimal motor blockade.

Does 0.5% ropivacaine infringe claim 1?

Not literally based on the stated concentration limitation. Claim 1 requires a concentration below 0.5% by weight.

Does the patent cover spinal or intrathecal ropivacaine?

No literal coverage is apparent because the claims require epidural administration. Intrathecal administration is a different route.

Does claim 7 cover a single epidural bolus?

No. Claim 7 requires continuous infusion. A single bolus may still be evaluated under claims 1 through 6.

Can an expired method patent block FDA approval of generic ropivacaine?

No. An expired patent cannot impose a remaining patent-term bar, although FDA approval still depends on applicable requirements for sterile injectable products and the approved reference product.

References

U.S. Patent No. 5,834,489. (1998). Method of treating pain with ropivacaine at low concentration. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (1996). Naropin (ropivacaine hydrochloride) injection prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	9302218	Jun 28, 1993

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	216237	⤷ Start Trial
Australia	692161	⤷ Start Trial
Australia	7086694	⤷ Start Trial
Brazil	9406865	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,834,489

Summary for Patent: 5,834,489